SAFETY DATA SHEET



SDS CA

Draxxin (Tulathromycin) Injectable Solution

Section 1. Identification

Product identifier : Draxxin (Tulathromycin) Injectable Solution

Other means of identification

: Draxxin 100 mg/ml solution for injection

Draxxin Injectable Solution

Draxxin®

Tulathromycin sterile injectable solution

Product type : Liquid.

Relevant identified uses of the substance or mixture and uses advised against

Identified uses

Veterinary product used as antibiotic agent

Uses advised against

Not for human use

Supplier's details : Zoetis Canada Inc.

16740 Trans-Canada Highway Kirkland, Quebec, H9H 4M7

1-800-461-0917

All Safety Data Sheets are available via our Zoetis Canada website at

https://www.zoetis.ca/sds/sds.aspx

Emergency telephone number (with hours of

operation)

: CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Rocky Mountain Poison & Drug Safety: 1-866-531-8896 Product support/Technical services: 1-888-963-8471

Zoetis Inc. 10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Section 2. Hazard identification

Classification of the substance or mixture

: EYE IRRITATION - Category 2A SKIN SENSITIZATION - Category 1

GHS label elements

Hazard pictograms



Signal word : Warning

Hazard statements : May cause an allergic skin reaction.

Causes serious eye irritation.

Precautionary statements

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 1/12

Section 2. Hazard identification

Prevention

: Wear protective gloves. Wear eye or face protection. Avoid breathing vapor. Wash thoroughly after handling. Contaminated work clothing should not be allowed out of the workplace.

Response

: IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice or attention. Take off contaminated clothing and wash it before reuse. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.

Storage

: Not applicable.

Disposal

: Dispose of contents and container in accordance with all local, regional, national and international regulations.

Supplemental label elements

: Avoid accidental injection.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture

Ingredient name	Synonyms	% (w/w)	Identifiers
propylene glycol	-	≥30 - ≤60	CAS: 57-55-6
tulathromycin A	-	≥10 - ≤30	CAS: 217500-96-4
Citric acid	Citric acid	≥1 - ≤5	CAS: 77-92-9

Ranges if listed above for hazardous ingredient(s) are prescribed ranges. The actual concentration(s) or actual concentration range(s) are being withheld as a trade secret.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First-aid measures

Description of necessary first aid measures

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact

: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse. In the event of accidental self injection or needle stick injury, wash the injury thoroughly with clean running water. Get medical attention immediately.

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 2/12

Section 4. First-aid measures

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. Rash. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Mild skin irritation. May cause an allergic skin reaction. Dermatitis. Causes serious eye irritation.

Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician

: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments Protection of first-aiders

- : No specific treatment.
- No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear

Section 5. Fire-fighting measures

Extinguishing media

Suitable extinguishing media

Unsuitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

: None known.

Specific hazards arising from the chemical

Hazardous thermal decomposition products : In a fire or if heated, a pressure increase will occur and the container may burst.

: Decomposition products may include the following materials:, carbon dioxide, carbon monoxide, nitrogen oxides

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: Keep unnecessary personnel away.

For emergency responders: Keep unnecessary personnel away. If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 3/12

Section 6. Accidental release measures

Environmental precautions

: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill

: Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

Section 7. Handling and storage

Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container. Avoid accidental injection.

Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

including any incompatibilities

Conditions for safe storage, : Do not store above the following temperature: 30°C (86°F). Do not freeze. Prolonged exposure to higher temperatures may adversely affect potency. Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
propylene glycol	CA Ontario Provincial (Canada, 6/2019) TWA 8 hours: 10 mg/m³. Form: Aerosol only TWA 8 hours: 155 mg/m³. Form: Vapour fraction TWA 8 hours: 50 ppm. Form: Vapour fraction
tulathromycin A	Zoetis OEL (ZOETIS OEL) TWA: 1 mg/m³.

Biological exposure indices

SDS CA Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025

Section 8. Exposure controls/personal protection

No exposure indices known.

Control Banding Approach

Not available.

Appropriate engineering controls

Environmental exposure controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection

Hand protection

: Wear appropriate chemical resistant gloves. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: In case of insufficient ventilation, wear suitable respiratory equipment.

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state : Liquid. [Solution]

Color : Colorless to slightly yellow

Odor : Not available.
Odor threshold : Not available.
pH : Not available.
Melting point/freezing point : Not available.
Boiling point or initial : Not available.
boiling point and boiling

range

Flash point : Not available.
Evaporation rate : Not available.
Flammability : Not available.
Lower and upper explosion : Not available.
limit/flammability limit

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 5/12

SDS CA

Section 9. Physical and chemical properties

Vapor pressure: Not available.Relative vapor density: Not available.Relative density: Not available.Solubility in water: Not available.Partition coefficient: n-: Not applicable.

octanol/water

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

Viscosity

Dynamic (room temperature): Not available.
 Kinematic (room temperature): Not available.
 Kinematic (40°C (104°F)): Not available.

Particle characteristics

Pmax : Not available.

Kst : Not available.

Min. Ignition Temperature : Not available.

(Dust)

Minimum ignition energy

(MIE) - dust cloud

: Not available.

Median particle size : Not applicable.

Section 10. Stability and reactivity

Reactivity: No specific test data related to reactivity available for this product or its ingredients.

Chemical stability : The product is stable.

Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

Conditions to avoid : Do not freeze. Avoid exposure to light, sunlight and elevated temperatures. Prolonged exposure to higher temperatures may adversely affect potency.

Incompatible materials : This material can be denatured or inactivated by a variety of organic solvents, salts

or heavy metals.

Remarks : Strong oxidizing agents

Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name Result

propylene glycol Rabbit - Dermal - LD50

20800 mg/kg **Mouse - Oral - LD50** 24900 mg/kg **Rat - Oral - LD50**

Rat - Oral - LD50 22000 mg/kg **Rat - Oral - LD50**

20 g/kg

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 6/12

SDS CA

Section 11. Toxicological information

Rabbit - Dermal - LD50

20800 mg/kg

tulathromycin A Rabbit - Dermal - LD50

> >2000 ma/ka Rat - Oral - LD50 3000 mg/kg

Conclusion/Summary [Product]

: Expected to be a low hazard for usual industrial or commercial handling

by trained personnel.

Result

Skin corrosion/irritation

propylene glycol

tulathromycin A

Citric acid

Citric acid

Product/ingredient name

Child - Skin - Moderate irritant

Duration of treatment/exposure: 96 hours Amount/concentration applied: 30 % C

Human - Skin - Mild irritant

Duration of treatment/exposure: 168 hours Amount/concentration applied: 500 mg Human - Skin - Moderate irritant Duration of treatment/exposure: 72 hours Amount/concentration applied: 104 mg I

Woman - Skin - Mild irritant

Duration of treatment/exposure: 96 hours Amount/concentration applied: 30 %

Rabbit - Skin - Mild irritant Rabbit - Skin - Mild irritant

Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg Rabbit - Skin - Moderate irritant Amount/concentration applied: 0.5 MI

Conclusion/Summary [Product]

: Causes mild skin irritation.

Serious eye damage/eye irritation

Product/ingredient name Result

propylene glycol Rabbit - Eyes - Mild irritant

> Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg

Rabbit - Eyes - Mild irritant

Amount/concentration applied: 100 mg

tulathromycin A Rabbit - Eyes - Irritant

Rabbit - Eyes - Severe irritant

Duration of treatment/exposure: 24 hours Amount/concentration applied: 750 ug

Conclusion/Summary [Product]

: Causes serious eye irritation.

Respiratory corrosion/irritation

Not available.

Citric acid

Conclusion/Summary [Product] : Due to partial or complete lack of data the classification is not possible.

Respiratory or skin sensitization

Product/ingredient name Result

SDS CA Draxxin (Tulathromycin) Injectable Solution

> Version : 1.01 Date of issue/Date of revision :11/7/2025 7/12

Section 11. Toxicological information

tulathromycin A **Guinea pig - skin**Result: Sensitizing

Skin

Conclusion/Summary [Product]: May cause an allergic skin reaction.

Respiratory

Conclusion/Summary [Product] : Due to partial or complete lack of data the classification is not possible.

Specific target organ toxicity (single exposure)

Not applicable.

Specific target organ toxicity (repeated exposure)

Not applicable.

Aspiration hazard

Not applicable.

Information on the likely routes of exposure

Not available.

Potential acute health effects

May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. Rash. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Mild skin irritation. May cause an allergic skin reaction. Dermatitis. Causes serious eye irritation.

Potential chronic health effects

Product/ingredient name Result

tulathromycin A Sub-chronic - Rat - Oral - NOAEL

15 mg/kg [3 months]

Sub-chronic - Dog - Oral - NOEL

5 mg/kg [3 months]

Chronic - Dog - Oral - NOAEL 5 mg/kg [7 days per week] [1 years] Sub-acute - Dog - Oral - NOAEL 15 mg/kg [7 days per week] [1 minutes] Sub-acute - Rat - Oral - NOAEL

50 mg/kg [7 days per week] [1 minutes]

General : Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

Germ cell mutagenicity

Product/ingredient name Result

Draxxin (Tulathromycin) Injectable Solution SDS CA

Version : 1.01 Date of issue/Date of revision :11/7/2025 8/12

Section 11. Toxicological information

tulathromycin A In vitro - Bacteria

OECD 471 [Bacterial Reverse Mutation Test]

Result: Negative

In vitro - Mammalian-Animal

OECD 473 [In vitro Mammalian Chromosomal Aberration Test]

Result: Negative

In vitro - Mammalian-Human

OECD 473 [In vitro Mammalian Chromosomal Aberration Test]

Result: Negative

In vitro - Mammalian-Animal

OECD 476 [In vitro Mammalian Cell Gene Mutation Test]

Result: Negative

In vivo - Mammalian-Animal

OECD 474 [Mammalian Erythrocyte Micronucleus Test]

Result: Negative

Conclusion/Summary [Product] : Due to partial or complete lack of data the classification is not possible.

Carcinogenicity

Not available.

Conclusion/Summary [Product]

Reproductive toxicity

Product/ingredient name

tulathromycin A

: Due to partial or complete lack of data the classification is not possible.

Result

Rat - Oral 200 mg/kg

Effects: NOAEL No effects at maximum dose.

Developmental: Negative

Rabbit - Oral 50 mg/kg

Effects: NOAEL No effects at maximum dose.

Developmental: Negative

Rat - Oral

OECD 416 [Two-Generation Reproduction Toxicity Study]

50 mg/kg

Effects: NOAEL No effects at maximum dose.

Developmental: Negative

Conclusion/Summary [Product] Numerical measures of toxicity

Acute toxicity estimates

: No known significant effects or critical hazards.

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
Draxxin (Tulathromycin) Injectable Solution	166666.8	N/A	N/A	N/A	N/A
propylene glycol	20000	20800	N/A	N/A	N/A
tulathromycin A	N/A	2500	N/A	N/A	N/A
Citric acid	3000	N/A	N/A	N/A	N/A

Other information

In the event of accidental injection, an allergic reaction may occur.

SDS CA Draxxin (Tulathromycin) Injectable Solution Version : 1.01 Date of issue/Date of revision :11/7/2025

Section 12. Ecological information

Toxicity

Product/ingredient name

propylene glycol

Result

Acute - LC50 - Fresh water

Crustaceans - Water flea - Ceriodaphnia dubia

Age: <24 hours 1020 mg/l [48 hours] Effect: Mortality

Acute - LC50 - Fresh water

Fish - Fathead minnow - Pimephales promelas

<u>Age</u>: ≤7 days 710 mg/l [96 hours] <u>Effect</u>: Mortality

Citric acid Acute - LC50 - Marine water

Crustaceans - Green crab - Carcinus maenas - Adult

160 mg/l [48 hours] Effect: Mortality

Conclusion/Summary [Product]

: No known significant effects or critical hazards. Avoid release to the

environment.

Persistence and degradability

Not available.

Conclusion/Summary [Product] : Not available.

Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
propylene glycol	-1.07	-	Low
tulathromycin A	-1.41	-	Low
Citric acid	-1.8	-	Low

Mobility in soil

Soil/Water partition

coefficient

: Not available.

Other adverse effects

No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods

: Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 10/12

Section 13. Disposal considerations

when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	TDG Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

Special precautions for user : Transport within user's premises: always transport in closed containers that are

upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

Section 15. Regulatory information

Canadian lists

Canadian NPRI : None of the components are listed.

CEPA Toxic substances : None of the components are listed.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Japan

Australia : Not determined.

Canada : Not determined.

China : Not determined.

Eurasian Economic Union

: Russian Federation inventory: All components are listed or exempted.

: Japan inventory (CSCL): Not determined.

Japan inventory (ISHL): Not determined.

New Zealand : Not determined.

Draxxin (Tulathromycin) Injectable Solution

SDS CA

Version : 1.01 Date of issue/Date of revision :11/7/2025

Section 15. Regulatory information

Philippines : Not determined.
Republic of Korea : Not determined.
Taiwan : Not determined.
Thailand : Not determined.
Turkey : Not determined.
United States : Not determined.

Viet Nam : All components are listed or exempted.

Section 16. Other information

History

Date of issue/Date of

revision

: 11/7/2025

Date of previous issue

Version

: 5/27/2025 : 1.01

Key to abbreviations

: ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor DOT = Department of Transportation

GHS = Globally Harmonized System of Classification and Labelling of Chemicals

HPR = Hazardous Products Regulations IATA = International Air Transport Association

IBC = Intermediate Bulk Container

IMDG = International Maritime Dangerous Goods

IMO = International Maritime Organization

LogPow = logarithm of the octanol/water partition coefficient

MARPOL = International Convention for the Prevention of Pollution From Ships,

1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)

N/A = Not available SGG = Segregation Group

TDG = Transportation of Dangerous Goods

UN = United Nations

Procedure used to derive the classification

Classification	Justification
EYE IRRITATION - Category 2A	Calculation method
SKIN SENSITIZATION - Category 1	Calculation method

References : Not available.

Notice to reader

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

Draxxin (Tulathromycin) Injectable Solution

Version : 1.01 Date of issue/Date of revision :11/7/2025 12/12